Skip to content

VX20-880-101: A study to assess the safety, tolerability and efficacy of potential new treatment for Type 1 Diabetes (T1D).

Type 1 Diabetes | Diabetes

This study is to assess the safety, tolerability and clinical efficacy of an investigational islet cell infusion, called VX-880.
This study consists of a screening visit up to 60 days before receiving the infusion and a procedure to infuse the investigational treatment. You will need to attend follow-up visits monthly after the infusion for the first year and about every three months after for approximately five years. You will also receive several medicines before, during, and after the infusion of the islet cells and will be asked to take medicines for the entire duration of the study. You will be monitored throughout the study using continuous glucose monitor, which will be provided to you.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 to 65

Participation Criteria

Inclusion Criteria:
Men and non-pregnant women between the ages of 18 and 65 who are diagnosed with T1D for at least 5 years and who do not always know when the blood sugar level is low may be eligible to participate in this clinical research study.
Exclusion Criteria:
Pregnant or planning to become pregnant during the study period

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Dayne Leon Izquierdo

[email protected]
780-492-2709
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00123763